2.1 The CRA Role, Data Integrity and Product Oversight

The CRA Role, Data Integrity and Product Oversight

According to ICH E6(R3), the purpose of trial monitoring is to verify three foundational pillars:

1. Protection of Human Subjects: That the rights, safety, and well-being of trial participants are actively protected throughout their participation.
2. Data Verifiability: That reported trial data are accurate, complete, and verifiable from authentic source documents.

Regulatory and Protocol Adherence: That the conduct of the trial complies with the currently approved protocol (and any approved amendments), ICH GCP, and applicable regulatory requirements.

The ALCOA+ Standard in Monitoring Practice

Data integrity is the bedrock upon which regulatory authorities evaluate drug efficacy and safety. The CRA verifies that every data point recorded on an electronic Case Report Form (eCRF) is supported by credible source documentation. The CCRA examination evaluates data integrity through the lens of the ALCOA+ framework:

• Attributable: Every piece of data, initial, signature, or electronic entry must clearly identify who created, observed, or recorded it.
• Legible: All handwriting, electronic records, and scanned images must be clearly readable. Corrections must preserve the original text using a single strike-through line, date, and initials.
• Contemporaneous: Record data contemporaneously; identify late entries honestly with the actual entry date and known event timing.
• Original: Preserve the primary record or a certified copy retaining the information needed to reconstruct the observation.
• Accurate: Information must be truthful, free from unexplained discrepancies, and precise.
• Complete: All required data fields, clinical evaluations, and concomitant medication logs must be present without omissions.
• Consistent: Information must be logically coherent across all trial documents (e.g., visit dates must match clinical notes, lab requisitions, and dispensation records).
• Enduring: Documentation must be preserved on stable media that survives throughout the mandatory retention period without degradation.
• Available: Records must be readily retrievable for review by monitors, auditors, and regulatory inspectors during on-site and remote visits.

Investigational Product (IP) Accountability

The CRA bears direct monitoring responsibility for verifying investigational product accountability under ICH E6(R3):

• Confirming that the IP is delivered only to authorized investigators and stored under protocol-specified environmental conditions (e.g., continuous temperature monitoring, humidity control, secure access).
• Verifying that storage temperature excursion logs are maintained and that excursions are immediately reported to the sponsor before dispensing affected product.
• Reconciling quantities received against quantities dispensed, returned by participants, and remaining in inventory.
• Ensuring participants receive appropriate instructions on dose administration, storage, and container return.
• Confirming that unused or expired IP is disposed of or returned to the sponsor in strict accordance with written sponsor instructions and local regulations.

Comparative Analysis: Distinguishing Roles in Clinical Trials

The CCRA examination frequently tests boundary distinctions between trial stakeholders. A monitor who fails to recognize their exact legal boundary risks committing serious protocol violations or creating liability for the sponsor.

Official sources

Checked October 18, 2026: ACRP CCRA programme, ACRP Initial Certification Handbook, June 2026, ACRP CCRA Exam Content Outline.